Trial · NCT02767531

Orlistat for the Treatment of Type I Hyperlipoproteinemia

NCT02767531, Phase 2, Completed, University of Texas Southwestern Medical Center; results first posted 2019-02-01

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Orlistat for the Treatment of Type I Hyperlipoproteinemia. Trials, record NCT02767531. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02767531

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Orlistat for the Treatment of Type I Hyperlipoproteinemia
NCT number: NCT02767531
Status: Completed
Phases: Phase 2
Enrollment: 2 participants, actual
Lead sponsor: University of Texas Southwestern Medical Center
Conditions: Hyperlipoproteinemia Type I, Hypertriglyceridemia
Interventions: Orlistat
First posted: 2016-05-10
Last updated: 2023-02-08
Results first posted: 2019-02-01

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Fasting Serum Triglycerides	3 days	Fasting blood samples were collected on three consequetive days at the end of each three month period. Mean values of the three days were calculated.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Fasting Serum Triglycerides	3 days	The patients were randomized to receive 3 months of orlistat or no therapy (off), then crossed over to the other arm, and this sequence was then repeated. Because only 2 patients participated, the results are provided per sequence and not per intervention.	mg/dL	MEAN

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Fasting Serum Triglycerides	Orlistat and Then Off Therapy	Period 1	705	Full Range 656 to 730	mg/dL
Fasting Serum Triglycerides	Off Therapy and Then Orlistat	Period 1	1827	Full Range 1266 to 2320	mg/dL
Fasting Serum Triglycerides	Orlistat and Then Off Therapy	Period 2	1511	Full Range 1226 to 1750	mg/dL
Fasting Serum Triglycerides	Off Therapy and Then Orlistat	Period 2	1007	Full Range 964 to 1040	mg/dL
Fasting Serum Triglycerides	Orlistat and Then Off Therapy	Period 3	758	Full Range 617 to 876	mg/dL
Fasting Serum Triglycerides	Off Therapy and Then Orlistat	Period 3	3121	Full Range 2780 to 3490	mg/dL
Fasting Serum Triglycerides	Orlistat and Then Off Therapy	Period 4	1614	Full Range 1540 to 1680	mg/dL
Fasting Serum Triglycerides	Off Therapy and Then Orlistat	Period 4	1181	Full Range 1122 to 1248	mg/dL

Source ClinicalTrials.gov

Participant flow24

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Period 1	STARTED	Orlistat Then Off Therapy	1
Period 1	STARTED	Off Orlistat Then Orlistat	1
Period 1	COMPLETED	Orlistat Then Off Therapy	1
Period 1	COMPLETED	Off Orlistat Then Orlistat	1
Period 1	NOT COMPLETED	Orlistat Then Off Therapy	0
Period 1	NOT COMPLETED	Off Orlistat Then Orlistat	0
Period 2	STARTED	Orlistat Then Off Therapy	1
Period 2	STARTED	Off Orlistat Then Orlistat	1
Period 2	COMPLETED	Orlistat Then Off Therapy	1
Period 2	COMPLETED	Off Orlistat Then Orlistat	1

1 to 10 of 24Source ClinicalTrials.gov

See all 24 participant flow

Adverse events2

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Bloating	Gastrointestinal disorders	Orlistat	2	2	2
other	Bloating	Gastrointestinal disorders	Off Therapy	0	2	0

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Orlistat	0	2
Total, all-cause mortality	Off Therapy	0	2
Total, other adverse events	Orlistat	2	2
Total, other adverse events	Off Therapy	0	2
Total, serious adverse events	Orlistat	0	2
Total, serious adverse events	Off Therapy	0	2

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
29659879	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Orlistat vs Off Therapy: deaths from any cause	Trial comparisons
Orlistat vs Off Therapy: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02767531

GET https://conductscience.org/api/trials/v1/NCT02767531/flow?page=2

API reference For AI assistants